Table 3.
Serum CEA, CA-125 levels and incidence of principal microscopic pharmacologic effects of ECH and E2 on female rat's uteri and mammary glands.
| Group | SHAM | OVX | E2 | ECH-L | ECH-M | ECH-H |
|---|---|---|---|---|---|---|
| Serum parameters | n = 8/group | |||||
| Serum CEA (pg/mL) | 341.82 ± 32.94 | 331.08 ± 36.97 | 511.11 ± 62.39##∗∗ | 346.03 ± 28.62 | 342.22 ± 42.57 | 330.67 ± 60.93 |
| Serum CA-125 (U/mL) | 1.89 ± 0.40 | 1.52 ± 0.39 | 2.43 ± 0.24##∗∗ | 1.37 ± 0.29* | 1.32 ± 0.41* | 1.08 ± 0.27#∗∗ |
| Uteri | n = 6/group | |||||
| Endometrium thickness changes | ++ | + | +++ | + | + | + |
| Immunohistochemical analysis of CEA | — | — | — | — | — | — |
| Mammary glands | n = 6/group | |||||
| Proliferative changes | + | — | ++ | — | — | — |
| Tubular changes | — | — | — | — | — | — |
| Ductal intraepithelial neoplasia | — | — | — | — | — | — |
| Carcinoma of breast | — | — | — | — | — | — |
| Immunohistochemical analysis of CEA | — | — | + | — | — | — |
The data are expressed as mean ± SD, n = 8. # P < 0.05 and ## P < 0.01 versus SHAM group, *P < 0.05 and **P < 0.01 versus OVX group at the same time point as evaluated by ANOVA.
+: minimal; ++: mild; +++: marked; —: not observed, the qualitative system according to [23] used previously.